The results of a clinical trial presented at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden comparing Jakafi (ruxolitinib) to best available therapy in patients with polycythemia vera (PV) revealed that Jakafi both reduces the risk of dying, and the incidence of blood clots.1
About Polycythemia Vera
Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. In PV the bone marrow makes too many blood cells, particularly red blood cells. These excess cells thicken the blood and can cause complications, such as a risk of blood clots or bleeding. Without treatment, PV can be life threatening and can eventually progress to more serious blood cancers, such as myelofibrosis or acute leukemia. Effective treatment, however, can significantly decrease risks and complications.
About Jakafi® (ruxolitinib)
Jakafi is a first-in-class JAK1/JAK2 inhibitor approved by the U.S. Food and Drug Administration for treatment of people with PV who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF.
About the PV Real-World Comparison Study
The new data presented at EHA compares overall survival and thrombosis (blood clots) rates using data from patients treated in the Jakafi arm of the RESPONSE clinical trial and patients treated in a real-world setting with best available therapy (BAT).1,2 RESPONSE was a global, open-label study that included patients with PV resistant to or intolerant of hydroxyurea, who were treated with either Jakafi or BAT and directly compared.
According to Dr. Alberto Alvarez-Larran, MD, Hematology Department, Hospital Clinic, Barcelona, Spain. “This latest research supports the use of Jakafi to help people with PV gain better control of their disease.
- Alvarez-Larran, et al. Comparison of Ruxolitinib Real-World Best Available Therapy in Terms Of overall Survival and Thrombosis in Patients with Polycythemia Vera who are Resistant or Intolerant to Hydroxyurea. EHA 2018. Abstract PF628.
Copyright © 2018 CancerConnect. All Rights Reserved.